I CLAIM:

1. A compound of the formula



(I)

wherein

$R^1$ is -H, -OH, -O($C_1$-$C_4$ alkyl), -OCOC$_6$H$_5$, -OCO($C_1$-$C_6$ alkyl), or -OSO$_2$($C_2$-$C_6$ alkyl);

$R^0$, $R^2$ and $R^3$ are each independently -H, -OH, -O($C_1$-$C_4$ alkyl), -OCOC$_6$H$_5$, -OCO($C_1$-$C_6$ alkyl), -OSO$_2$($C_2$-$C_6$ alkyl) or halo;

$R^4$ is 1-piperidinyl, 1-pyrrolidinyl, methyl-1-pyrrolidinyl, dimethyl-1-pyrrolidinyl, 4-morpholino, dimethylamino, diethylamino, diisopropylamino, or 1-hexamethyleneimino;

n is 2 or 3;

X is –S- or -HC=CH-;

G is –O-, -S-, -SO-, SO$_2$, or –N($R^5$)-, wherein $R^5$ is –H or $C_1$-$C_4$ alkyl; and

Y is –O-, -S-, -NH-, -NMe-, or -CH$_2$-;

or a pharmaceutically acceptable salt thereof.

2. A compound of Claim 1 of the formula



(IC)

wherein

$R^1$ is -H, -OH, -O($C_1$-$C_4$ alkyl), -OCOC$_6$H$_5$, -OCO($C_1$-$C_6$ alkyl), or -OSO$_2$($C_2$-$C_6$ alkyl);

$R^2$ and $R^3$ are each independently -H, -OH, -O($C_1$-$C_4$ alkyl), -OCOC$_6$H$_5$, -OCO($C_1$-$C_6$ alkyl), -OSO$_2$($C_2$-$C_6$ alkyl) or halo;

$R^4$ is 1-piperidinyl, 1-pyrrolidinyl, methyl-1-pyrrolidinyl, dimethyl-1-pyrrolidinyl, 4-morpholino, dimethylamino, diethylamino, diisopropylamino, or 1-hexamethyleneimino;

n is 2 or 3;

X is –S- or -HC=CH-;

G is –O-, -S-, -SO-, SO$_2$, or –N($R^5$)-, wherein $R^5$ is –H or $C_1$-$C_4$ alkyl; and

Y is –O-, -S-, -NH-, -NMe-, or -CH$_2$-;

or a pharmaceutically acceptable salt thereof.

3. A compound according to either of Claims 1 or 2 wherein G is –O-.

4. A compound according to any of Claims 1 to 3 wherein Y is –O-.

5. A compound according to any of Claims 1 to 4 wherein n is 2.

6. A compound according to any of Claims 1 to 5 wherein $R^1$ is –OH or –OCH$_3$.

7. A compound according to any of Claims 1 to 6 wherein $R^1$ is –OH.

8. A compound according to any of Claims 1 to 7 wherein $R^4$ is 1-piperidinyl or 1-pyrrolidinyl.

9. A compound according to any of Claims 1 to 8 wherein $R^4$ is 1-piperidinyl.

10. A compound according to any of Claims 1 to 9 wherein two of $R^0$, $R^2$ and $R^3$ is –H.

11. A compound according to any of Claims 1 to 9 wherein two of $R^0$, $R^2$ and $R^3$ is –H and the other is –OH.

12. A compound according to any of Claims 1 to 9 wherein all of $R^0$, $R^2$ and $R^3$ are –H.

13. A compound according to any of Claims 1 to 9 wherein at least one of $R^0$, $R^2$, and $R^3$ is halo and the other or others is –H.

14. A compound according to any of Claims 1 to 13 wherein X is –S-.

15. A compound according to any of Claims 1 to 13 wherein X is –HC=CH-.

16. A compound according to Claim 1 wherein said compound is 5-[4-(2-piperidin-1-yl-ethoxy)-phenyl]-5,11-dihydro-6-oxa-12-thia-dibenzo[a,f]azulen-2-ol or a pharmaceutically acceptable salt thereof.

17. A compound according to Claim 1 wherein said compound is 13-[4-(2-piperidin-1-yl-ethoxy)-phenyl]-7,13-dihydro-12-oxa-benzo[4,5]cyclohepta[1,2-a]naphthalen-3-ol or a pharmaceutically acceptable salt thereof.

18. A pharmaceutical composition comprising a compound according to Claim 1 or a pharmaceutically acceptable salt thereof, and optionally an effective amount of estrogen and progestin, in combination with a pharmaceutically acceptable salt, diluent, or excipient.

19. A method for inhibiting a disease associated with estrogen deprivation comprising administering to a patient in need thereof a therapeutically effective amount of a compound according to any one of Claims 1 through 17.

20. A method according to Claim 19 wherein said patient is a human.

21. A method according to Claim 20 wherein said patient is a postmenopausal female.

22. A method according to any of Claims 19 through 21 wherein said disease associated with estrogen deprivation is bone loss.

23. A method according to any of Claims 19 through 21 wherein said disease associated with estrogen deprivation is cardiovascular disease.

24. A method for inhibiting a disease associated with an aberrant physiological response to endogenous estrogen comprising administering to a patient in need thereof a therapeutically effective amount of a compound according to any one of Claims 1 through 17.

25. A method according to Claim 24 wherein said patient is a human.

26. A method according to Claim 25 wherein said patient is a postmenopausal female.

27. A method according to any of Claims 24 through 26 wherein the disease associated with an aberrant physiological response to endogenous estrogen is estrogen dependent cancer.

28. A method according to Claim 27 wherein said cancer is breast cancer.

29. A method according to any of Claims 24 through 26 wherein the disease associated with an aberrant physiological response to endogenous estrogen is endometriosis.

30. A method according to any of Claims 24 through 26 wherein the disease associated with an aberrant physiological response to endogenous estrogen is uterine fibrosis.

31. A compound of the formula



(4)

wherein

$R^1$ is -H, -OH, -O($C_1$-$C_4$ alkyl), -OCOC$_6$H$_5$, -OCO($C_1$-$C_6$ alkyl), or -OSO$_2$($C_2$-$C_6$ alkyl);

$R^{0a}$, $R^{2a}$ and $R^{3a}$ are each independently -H, -OPg, or halo, wherein Pg is a hydroxy protecting group;

$R^4$ is 1-piperidinyl, 1-pyrrolidinyl, methyl-1-pyrrolidinyl, dimethyl-1-pyrrolidinyl, 4-morpholino, dimethylamino, diethylamino, diisopropylamino, or 1-hexamethyleneimino;

ART 34 AMDT



n is 2 or 3;

$G^1$ is –O–, -S–, or –N($R^5$)–, wherein $R^5$ is –H or $C_1$-$C_4$ alkyl; and

Y is –O–, -S–, -NH–, -NMe–, or -$CH_2$–;

or a pharmaceutically acceptable salt thereof.

32. A compound according to Claim 31 wherein said compound is [6-hydroxy-2-(2-hydroxy-benzyl)-benzo[b]thiophen-3-yl]-[4-(2-piperidin-1-yl-ethoxy)-phenyl]-methanone.

33. A compound of the formula



(10)

wherein

$R^1$ is -H, -OH, -O($C_1$-$C_4$ alkyl), -OCOC$_6$H$_5$, -OCO($C_1$-$C_6$ alkyl), or -$OSO_2$($C_2$-$C_6$ alkyl);

$R^{0a}$, $R^{2a}$ and $R^{3a}$ are each independently -H, -OPg, or halo, wherein Pg is a hydroxy protecting group;

$R^4$ is 1-piperidinyl, 1-pyrrolidinyl, methyl-1-pyrrolidinyl, dimethyl-1-pyrrolidinyl, 4-morpholino, dimethylamino, diethylamino, diisopropylamino, or 1-hexamethyleneimino;

n is 2 or 3;

$G^1$ is –O–, -S–, or –N($R^5$)–, wherein $R^5$ is –H or $C_1$-$C_4$ alkyl; and

Y is –O–, -S–, -NH–, -NMe–, or -$CH_2$–;

or a pharmaceutically acceptable salt thereof.

34. A compound according to Claim 33 wherein said compound is [6-hydroxy-2-(2-hydroxy-benzyl)-naphthalen-1-yl]-[4-(2-piperidin-1-yl-ethoxy)-phenyl]-methanone.

35. A compound of the formula



(II)

wherein

$R^1$ is -H, -OH, -O($C_1$-$C_4$ alkyl), -OCOC$_6$H$_5$, -OCO($C_1$-$C_6$ alkyl), or -OSO$_2$($C_2$-$C_6$ alkyl);

$R^{2a}$, $R^{2a}$ and $R^{3a}$ are each independently -H, -OPg, or halo, wherein Pg is a hydroxy protecting group;

$R^4$ is 1-piperidinyl, 1-pyrrolidinyl, methyl-1-pyrrolidinyl, dimethyl-1-pyrrolidinyl, 4-morpholino, dimethylamino, diethylamino, diisopropylamino, or 1-hexamethyleneimino;

$n$ is 2 or 3;

$G^1$ is –O-, -S-, or –N($R^5$)-, wherein $R^5$ is –H or $C_1$-$C_4$ alkyl; and

Y is –O-, -S-, -NH-, -NMe-, or -$CH_2$-;

or a pharmaceutically acceptable salt thereof.

36. A compound according to Claim 35 wherein said compound is 6-(2-hydroxy-benzyl)-5-{hydroxy-[4-(2-piperidin-1-yl-ethoxy)-phenyl]-methyl}-naphthalen-2-ol.